Human breast cancer growth inhibited in vivo by a dominant negative pleiotrophin mutant.
Pleiotrophin (PTN) is a recently described 18- kDa heparin binding growth/differentiation factor. It also is a proto-oncogene; cells transformed by the Ptn gene form highly angiogenic tumors when implanted into the nude mouse. PTN may be an important regulator of transformation in other tumors, because constitutively high levels of expression of the pleiotrophin (Ptn) gene are found in human breast cancer and other malignant cell lines, and its levels of expression are high in many human tumor specimens. To determine whether PTN is an important regulator of the malignant phenotype of human breast cancer cells, we constructed a mutant cDNA to encode a truncated PTN designed to heterodimerize with the product of the endogenous Ptn gene during processing. The mutant gene product blocked transformation of NIH 3T3 cells by the wild type (wt) Ptn gene product. The mutant Ptn cDNA was then introduced into human breast cancer MDA-MB-231 cells, and clonal lines that stably express the mutant Ptn cDNA were selected. The truncated PTN was shown to form heterodimers with the endogenous Ptn gene product in these cells. Furthermore, the MDA-MB-231 cells that express the mutant Ptn gene were no longer transformed; they failed to form plaques or colonies in soft agar and were unable to form tumors in the athymic nude mouse. The results establish an important role of PTN in the dysregulated growth of human breast cancer cells and suggest that constitutive expression of PTN may be essential to the malignant phenotype of human breast cancers in vivo.
Zhang
N
N
Division of Growth Regulation, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Zhong
R
R
Wang
Z Y
ZY
Deuel
T F
TF
D016475:3T3 Cells; D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology*; D002352:Carrier Proteins / Q000235:genetics* / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D016207:Cytokines / Q000235:genetics* / Q000494:pharmacology; D018076:DNA, Complementary / Q000378:metabolism; D019281:Dimerization; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D008934:Mitogens / Q000235:genetics* / Q000494:pharmacology; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D010641:Phenotype; D000090063:Proto-Oncogene Mas; D014162:Transfection; D014407:Tumor Cells, Cultured
D002352:Carrier Proteins; D016207:Cytokines; D018076:DNA, Complementary; C000715470:MAS1 protein, human; D008934:Mitogens; D000090063:Proto-Oncogene Mas; C066845:pleiotrophin